This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Usmani, Saad
| Item Type | Name |
|
Academic Article
|
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
|
|
Academic Article
|
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
|
|
Academic Article
|
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
|
|
Academic Article
|
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
|
|
Academic Article
|
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
|
|
Academic Article
|
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
|
|
Academic Article
|
Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens.
|
|
Academic Article
|
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
|
|
Academic Article
|
Teclistamab, a B-cell maturation antigen???CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
|
|
Concept
|
Antineoplastic Agents, Immunological
|
|
Academic Article
|
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
|
|
Academic Article
|
Teclistamab in Relapsed or Refractory Multiple Myeloma.
|
|
Academic Article
|
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
|
|
Academic Article
|
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study.
|
- Antineoplastic Agents Immunological